UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer

Journal of clinical oncology, 2018-03, Vol.36 (9), p.884-890

2018

Volltextzugriff (PDF)

Drug Resistance and the Role of Combination Chemotherapy in Improving Patient Outcomes

International Journal of Breast Cancer, 2013-01, Vol.2013 (2013), p.26-40

2013

Volltextzugriff (PDF)

Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor

Journal of clinical oncology, 2013-06, Vol.31 (17), p.2128-2135

2013

Volltextzugriff (PDF)

Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

Journal of clinical oncology, 2010-12, Vol.28 (35), p.5132-5139

2010

Volltextzugriff (PDF)

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

Journal of clinical oncology, 2011-04, Vol.29 (10), p.1252-1260

2011

Volltextzugriff (PDF)

nab-Paclitaxel mechanisms of action and delivery

Journal of controlled release, 2013-09, Vol.170 (3), p.365-372

Yardley, Denise A.

2013

Volltextzugriff (PDF)

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer

Journal of clinical oncology, 2015-05, Vol.33 (14), p.1609-1619

2015

Volltextzugriff (PDF)

Tracheoesophageal Fistula Formation in Patients With Lung Cancer Treated With Chemoradiation and Bevacizumab

Journal of clinical oncology, 2010-01, Vol.28 (1), p.43-48

2010

Volltextzugriff (PDF)

Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer

Journal of clinical oncology, 2013-08, Vol.31 (23), p.2870-2878

2013

Volltextzugriff (PDF)

Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions

Breast Cancer: Basic and Clinical Research, 2013-01, Vol.2013 (2013), p.7-22

Yardley, Denise A.

2013

Volltextzugriff (PDF)

Molecular Profiling in Unknown Primary Cancer: Accuracy of Tissue of Origin Prediction

The oncologist (Dayton, Ohio), 2010-05, Vol.15 (5), p.500-506

2010

Volltextzugriff (PDF)

MONALEESA clinical program: a review of ribociclib use in different clinical settings

Future oncology (London, England), 2019-08, Vol.15 (23), p.2673-2686

Yardley, Denise A

2019

Volltextzugriff (PDF)

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

The New England journal of medicine, 2017-07, Vol.377 (2), p.122-131

2017

Volltextzugriff (PDF)

Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin’s Lymphoma

Journal of clinical oncology, 2002-10, Vol.20 (20), p.4261-4267

2002

Volltextzugriff (PDF)

Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study

NPJ breast cancer, 2021-05, Vol.7 (1), p.57-57, Article 57

2021

Volltextzugriff (PDF)

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR + /HER2 - Metastatic Breast Cancer

Clinical cancer research, 2017-09, Vol.23 (17), p.5218-5224

2017

Volltextzugriff (PDF)

A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer

Clinical breast cancer, 2019-02, Vol.19 (1), p.1-9

2019

Volltextzugriff (PDF)

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer

The New England journal of medicine, 2015-01, Vol.372 (2), p.134-141

2015

Volltextzugriff (PDF)

Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer

Journal of clinical oncology, 2014-12, Vol.32 (34), p.3840-3847

2014

Volltextzugriff (PDF)

Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

Journal of clinical oncology, 2019-08, Vol.37 (22), p.1868-1875

2019

Volltextzugriff (PDF)

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

European journal of cancer (1990), 2012-11, Vol.48 (16), p.3082-3092

2012

Volltextzugriff (PDF)

Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR + /HER2 - Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1)

Clinical cancer research, 2021-08, Vol.27 (15), p.4177-4185

2021

Volltextzugriff (PDF)

Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab

Cancer discovery, 2021-10, Vol.11 (10), p.2474-2487

2021

Volltextzugriff (PDF)

1 – 25 von 305

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(301)
Mit Volltextzugriff
(272)

Publikationsform

Artikel
(304)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(152)
Science & Technology
(152)
Humans
(140)
Oncology
(139)
Female
(135)
Middle Aged
(110)
Aged
(99)
Adult
(96)
Breast Neoplasms - Drug Therapy
(92)
Breast Cancer
(75)
Breast Neoplasms - Pathology
(73)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(62)
Treatment Outcome
(59)
Aged, 80 And Over
(51)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(47)
Disease-Free Survival
(42)
Chemotherapy
(41)
Tumors
(37)
Cancer Therapies
(36)
Breast Neoplasms - Mortality
(33)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer

Drug Resistance and the Role of Combination Chemotherapy in Improving Patient Outcomes

Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor

Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial

nab-Paclitaxel mechanisms of action and delivery

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer

Tracheoesophageal Fistula Formation in Patients With Lung Cancer Treated With Chemoradiation and Bevacizumab

Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer

Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial

Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions

Molecular Profiling in Unknown Primary Cancer: Accuracy of Tissue of Origin Prediction

MONALEESA clinical program: a review of ribociclib use in different clinical settings

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin’s Lymphoma

Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR + /HER2 - Metastatic Breast Cancer

A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer

Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer

Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR + /HER2 - Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1)

Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab

Suchergebnisse filtern